Skye Bioscience Demonstrates Prominent Role of Peripheral CB1 Inhibition and Achieves Significant Weight Loss with Novel CB1-inhibiting Antibody, Nimacimab, in Preclinical Model
Stock Information for Skye Bioscience Inc.
Loading
Please wait while we load your information from QuoteMedia.